Spruce Street Capital’s Centessa Pharmaceuticals CNTA Stock Holding History

Spruce Street Capital’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-489,849	Closed	-$19.5M	–	31
2026 Q1	$19.5M	Buy	489,849 +411,852	+528%	+$10.5M	4.68%	7
2025 Q4	$1.95M	Buy	+77,997	New	+$1.98M	0.64%	23

Spruce Street Capital's CNTA Position: Q2 2026 in Review

Spruce Street Capital sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 489,849 shares — an estimated $19.5M sold.

Spruce Street Capital first reported a position in CNTA in Q4 2025 and held it in 2 quarters. The position peaked at $19.5M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Spruce Street Capital reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Spruce Street Capital sold 489,849 Centessa Pharmaceuticals shares in Q2 2026, an estimated $19.5M.
Spruce Street Capital first reported a position in Centessa Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Spruce Street Capital's Centessa Pharmaceuticals position peaked at $19.5M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Spruce Street Capital's 13F filing for Q2 2026, filed 13 Aug 2026.